Johnson & Johnson (JNJ) — Stock Price, Financials & Analysis

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Key Statistics — JNJ

  • Latest Close: $259.80
  • Market Cap: $626.09B
  • P/E Ratio (TTM): 30.2
  • EPS (TTM): $8.61
  • Dividend Yield: 205.00%
  • Beta: 0.23
  • 52-Week High: $274.90
  • 52-Week Low: $171.81
  • Profit Margin: 21.5%
  • Return on Equity: 25.7%
  • Debt to Equity: 57.7

Sector: Healthcare — Drug Manufacturers - General

Income Statement — JNJ

  • 2021: Revenue N/A, Net Income N/A
  • 2022: Revenue $79.99B, Net Income $17.94B
  • 2023: Revenue $85.16B, Net Income $35.15B
  • 2024: Revenue $88.82B, Net Income $14.07B
“”Wednesday, August 12, 2026
Minimaxmax⁡x∈Δmin⁡y∈Δ x⊤ ⁣A y=v∗\max_{x \in \Delta} \min_{y \in \Delta} \, x^\top\! A \, y = v^*maxx∈Δ​miny∈Δ​x⊤Ay=v∗§Zero-Sum∑i=1nui(s)=0    ∀ s∈S\textstyle\sum_{i=1}^{n} u_i(s) = 0 \;\; \forall \, s \in S∑i=1n​ui​(s)=0∀s∈S§Nash Eq.x∗⊤ ⁣Ay≥x∗⊤ ⁣Ay∗≥x⊤ ⁣Ay∗x^{*\top}\! A y \geq x^{*\top}\! A y^* \geq x^\top\! A y^*x∗⊤Ay≥x∗⊤Ay∗≥x⊤Ay∗§ExpectedE[u1]=x⊤ ⁣A y\mathbb{E}[u_1] = x^\top\! A \, yE[u1​]=x⊤Ay§RegretRT=max⁡i∑t=1Tuit−∑t=1TuattR_T = \max_i \sum_{t=1}^{T} u_i^t - \sum_{t=1}^{T} u_{a_t}^tRT​=maxi​∑t=1T​uit​−∑t=1T​uat​t​§LP Dualmin⁡y,ww    s.t.    Ay≤w⋅1\min_{y,w} w \;\; \text{s.t.} \;\; Ay \leq w \cdot \mathbf{1}miny,w​ws.t.Ay≤w⋅1§Payoffu1(i,j)=aij,    u2(i,j)=−aiju_1(i,j) = a_{ij}, \;\; u_2(i,j) = -a_{ij}u1​(i,j)=aij​,u2​(i,j)=−aij​§Minimaxmax⁡x∈Δmin⁡y∈Δ x⊤ ⁣A y=v∗\max_{x \in \Delta} \min_{y \in \Delta} \, x^\top\! A \, y = v^*maxx∈Δ​miny∈Δ​x⊤Ay=v∗§Zero-Sum∑i=1nui(s)=0    ∀ s∈S\textstyle\sum_{i=1}^{n} u_i(s) = 0 \;\; \forall \, s \in S∑i=1n​ui​(s)=0∀s∈S§Nash Eq.x∗⊤ ⁣Ay≥x∗⊤ ⁣Ay∗≥x⊤ ⁣Ay∗x^{*\top}\! A y \geq x^{*\top}\! A y^* \geq x^\top\! A y^*x∗⊤Ay≥x∗⊤Ay∗≥x⊤Ay∗§ExpectedE[u1]=x⊤ ⁣A y\mathbb{E}[u_1] = x^\top\! A \, yE[u1​]=x⊤Ay
0∑×$0 sometimesAlpha v0.1.0

The Shounya

HomeScreenerHeatmapSectorsDividendsCompareWatchlistPortfolioChartTechnicalScannerEarningsCorrelationSector AnalysisInsidersCongressNewsLearnAboutStatus
← Home← ScreenerChart TerminalTechnical
JNJHealthcare

Johnson & Johnson — Healthcare · Drug Manufacturers - General

$259.80-2.01 (-0.77%)
Mkt Cap
$626.09B
P/E
30.2
EPS
$8.61
Beta
0.23
Yield
205.00%
52W Hi
$274.90
52W Lo
$171.81
Vol
8.3M

Price History

Chart Terminal →Technical Analysis →

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
138,200
HQ
New Brunswick, NJ, United States
Web
jnj.com

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Top Executives

NameTitleTotal Pay
Mr. Joaquin DuatoCEO & Chairman$6.5M

Financial Statements

✓
Profitable
4/5 periods
✓
Revenue Growing
+6.0% latest, 3/3 up
✓
Earnings Growing
+90.6% latest, 2/3 up
✗
Pays Dividend
No dividends
✓
Positive Margin
21.5% net margin

Johnson & Johnson

Healthcare \u00b7 Drug Manufacturers - General

Market Cap$626.09B
Trailing P/E30.2
Forward P/E21.1
EPS (trailing)$8.61
EPS (forward)$12.31
Gross Margin68.1%
Operating Margin29.2%
Profit Margin21.5%
Dividend Rate$5.36/share
Dividend Yield205.0%
Payout Ratio60.8%

Revenue & Net Income

2021 – 2025, Annual

Revenue

Net Income

Profit Margins

2021 – 2025, Annual

Earnings Per Share

2021 – 2025, Annual

Dividends

No dividend history available.

Price Ranges

52-Week
$171.81$274.90
Fwd P/E21.1
Avg Volume8.3M
Shares Out2.41B

Key Ratios

Gross Margin68.1%
Operating Margin29.2%
Profit Margin21.5%
ROE25.7%
ROA8.6%
P/B7.4
D/E57.71
Current Ratio1.09
Dividend Rate$5.36
Payout Ratio60.8%

Cash & Debt

Cash 30%Debt 70%
Total Cash$20.76B
Total Debt$49.04B
Net Cash$-28.28B
Free Cash Flow$16.89B
Operating CF$27.61B

Ratings Snapshot

2.8 / 5
P/E2/5(30.2)
P/B2/5(7.4)
ROE5/5(25.7)
ROA4/5(8.6)
D/E1/5(57.7)
Liquidity3/5(1.1)

Growth Pulse

Revenue Growth+6.6%
Earnings Growth-0.9%

Analyst Recommendations

0m
Buy (23 analysts)
5
11
6
Strong Buy: 5
Buy: 11
Hold: 6
Sell: 1
Strong Sell: 0
MonthStr BuyBuyHoldSellStr Sell
0m511610
-1m511610
-2m510710
-3m510801

Income Snapshot 2025

Revenue
$94.2B
Net Income
$26.8B
Gross Margin
67.9%
Net Margin
28.5%
Op. Income
$25.6B
EPS
$11.13

Balance Sheet

2021 – 2025, Annual
Debt / Equity0.59x
Owns more than it owes — healthy
Current Ratio1.03x
Can cover short-term bills
Net Debt$28.22B
Total debt minus cash on hand

Assets vs Liabilities vs Equity

Assets = Liabilities + Equity. The green bar is what's left for shareholders after paying all debts.

Cash vs Debt

How much cash the company has on hand vs how much it owes in total debt.

Period Detail

PeriodAssetsLiabilitiesEquityCashDebtD/E
2021N/AN/AN/AN/AN/A—
2022$187.38B$110.57B$76.80B$12.89B$39.64B0.52x
2023$167.56B$98.78B$68.77B$21.86B$29.33B0.43x
2024$180.10B$108.61B$71.49B$24.11B$36.63B0.51x
2025$199.21B$117.67B$81.54B$19.71B$47.93B0.59x

Balance Sheet Snapshot 2025

Total Assets$199.21B
Total Liabilities$117.67B
Equity$81.54B
Retained EarningsN/A
Goodwill$48.77B
Long-Term Debt$39.44B

Cash Flow Statement

2022 – 2025, Annual

Operating · Investing · Financing

Operating — cash from core business.Investing — buying/selling long-term assets.Financing — debt, equity & dividends.

Free Cash Flow

Operating cash flow minus capital expenditure — the cash available after maintaining operations.

PeriodOperatingInvestingFinancingFCFCapEx
2022$21B$-12B$-9B$17B$-4B
2023$23B$878M$-16B$18B$-5B
2024$24B$-19B$-3B$18B$-6B
2025$25B$-24B$-6B$19B$-5B

Capital Allocation 2025

CapEx$5.22B
Dividends Paid$12.38B
Buybacks$5.95B
Debt Repaid$14.09B
Debt Issued$23.72B
Net Change Cash$-4.60B

Price History

Chart Terminal →Technical Analysis →

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
138,200
HQ
New Brunswick, NJ, United States
Web
jnj.com

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Top Executives

NameTitleTotal Pay
Mr. Joaquin DuatoCEO & Chairman$6.5M

Price Ranges

52-Week
$171.81$274.90
Fwd P/E21.1
Avg Volume8.3M
Shares Out2.41B

Key Ratios

Gross Margin68.1%
Operating Margin29.2%
Profit Margin21.5%
ROE25.7%
ROA8.6%
P/B7.4
D/E57.71
Current Ratio1.09
Dividend Rate$5.36
Payout Ratio60.8%

Cash & Debt

Cash 30%Debt 70%
Total Cash$20.76B
Total Debt$49.04B
Net Cash$-28.28B
Free Cash Flow$16.89B
Operating CF$27.61B

Ratings Snapshot

2.8 / 5
P/E2/5(30.2)
P/B2/5(7.4)
ROE5/5(25.7)
ROA4/5(8.6)
D/E1/5(57.7)
Liquidity3/5(1.1)

Growth Pulse

Revenue Growth+6.6%
Earnings Growth-0.9%

Analyst Recommendations

0m
Buy (23 analysts)
5
11
6
Strong Buy: 5
Buy: 11
Hold: 6
Sell: 1
Strong Sell: 0
MonthStr BuyBuyHoldSellStr Sell
0m511610
-1m511610
-2m510710
-3m510801

Financial Statements

✓
Profitable
4/5 periods
✓
Revenue Growing
+6.0% latest, 3/3 up
✓
Earnings Growing
+90.6% latest, 2/3 up
✗
Pays Dividend
No dividends
✓
Positive Margin
21.5% net margin

Johnson & Johnson

Healthcare \u00b7 Drug Manufacturers - General

Market Cap$626.09B
Trailing P/E30.2
Forward P/E21.1
EPS (trailing)$8.61
EPS (forward)$12.31
Gross Margin68.1%
Operating Margin29.2%
Profit Margin21.5%
Dividend Rate$5.36/share
Dividend Yield205.0%
Payout Ratio60.8%

Revenue & Net Income

2021 – 2025, Annual

Revenue

Net Income

Profit Margins

2021 – 2025, Annual

Earnings Per Share

2021 – 2025, Annual

Dividends

No dividend history available.

Income Snapshot 2025

Revenue
$94.2B
Net Income
$26.8B
Gross Margin
67.9%
Net Margin
28.5%
Op. Income
$25.6B
EPS
$11.13

Balance Sheet

2021 – 2025, Annual
Debt / Equity0.59x
Owns more than it owes — healthy
Current Ratio1.03x
Can cover short-term bills
Net Debt$28.22B
Total debt minus cash on hand

Assets vs Liabilities vs Equity

Assets = Liabilities + Equity. The green bar is what's left for shareholders after paying all debts.

Cash vs Debt

How much cash the company has on hand vs how much it owes in total debt.

Period Detail

PeriodAssetsLiabilitiesEquityCashDebtD/E
2021N/AN/AN/AN/AN/A—
2022$187.38B$110.57B$76.80B$12.89B$39.64B0.52x
2023$167.56B$98.78B$68.77B$21.86B$29.33B0.43x
2024$180.10B$108.61B$71.49B$24.11B$36.63B0.51x
2025$199.21B$117.67B$81.54B$19.71B$47.93B0.59x

Balance Sheet Snapshot 2025

Total Assets$199.21B
Total Liabilities$117.67B
Equity$81.54B
Retained EarningsN/A
Goodwill$48.77B
Long-Term Debt$39.44B

Cash Flow Statement

2022 – 2025, Annual

Operating · Investing · Financing

Operating — cash from core business.Investing — buying/selling long-term assets.Financing — debt, equity & dividends.

Free Cash Flow

Operating cash flow minus capital expenditure — the cash available after maintaining operations.

PeriodOperatingInvestingFinancingFCFCapEx
2022$21B$-12B$-9B$17B$-4B
2023$23B$878M$-16B$18B$-5B
2024$24B$-19B$-3B$18B$-6B
2025$25B$-24B$-6B$19B$-5B

Capital Allocation 2025

CapEx$5.22B
Dividends Paid$12.38B
Buybacks$5.95B
Debt Repaid$14.09B
Debt Issued$23.72B
Net Change Cash$-4.60B
0∑×

Free market data & analysis tools.

Markets
HomeScreenerHeatmapSectorsEarnings
Tools
WatchlistCompareChart TerminalTechnical
Research
CongressInsidersDividendsCorrelation
© 2026 ShounyaAlpha v0.1.0Not financial advice · hanabira.org